Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs (BIIB34) Price & Analysis

Q: Is Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs overvalued?

According to Wall Street analysts Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Which hedge fund is a major shareholder of Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs?

Currently, no hedge funds are holding shares in BR:BIIB34

― Followers

BIIB34 Stock Chart & Stats

R$188.28

R$0.00(0.00%)

Sep 30, 2026

―

Day’s Range― - ―

52-Week RangeR$110.07 - R$200.11

Previous CloseN/A

VolumeN/A

Average Volume (3M)5.00

Market Cap

R$173.92B

Enterprise ValueR$181.20K

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)37516.4

Beta-0.06

Next Earnings

Oct 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)<0.01

Shares Outstanding886,506,300

10 Day Avg. Volume2

30 Day Avg. Volume5

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs News

Mizuho biotech analysts hold an analyst/industry conference call

Biotech AnaLyst Syed, along with the Biotech Research Team, discuss Vaxcyte (PCVX), ahead of VAX-31 Ph3 OPUS-1 readout...

6h ago

BBIO

BIIB

Biogen publishes results from adolescent subgroup of VALIANT study

Biogen (BIIB) announced the publication of results from a prespecified adolescent subgroup analysis of the Phase 3 VALIANT...

14d ago

BIIB

Eisai, Biogen announce Leqembi Pen has been approved in Japan

Eisai (ESAIY) and Biogen (BIIB) announced that Leqembi Pen, the subcutaneous formulation of the anti-amyloid beta protofibril antibody...

16d ago

BIIB

Private Markets: Gimlet Labs, Encoded Therapeutics secure new funding

Investors poured fresh capital into applied AI and precision biotech this week, with Gimlet Labs raising $300M at...

21d ago

Biogen price target raised to $175 from $165 at HSBC

HSBC raised the firm’s price target on Biogen (BIIB) to $175 from $165 and keeps a Reduce rating...

22d ago

BIIB

Stoke Therapeutics, Biogen present long-term data on Zorevunersen

“Stoke Therapeutics (STOK) and Biogen Inc. (BIIB) announced presentations of data at the 16th European Epilepsy Congress taking...

28d ago

BIIB

STOK

Biogen price target raised to $245 from $225 at Piper Sandler

Piper Sandler raised the firm’s price target on Biogen (BIIB) to $245 from $225 and keeps an Overweight...

29d ago

BIIB

Biogen, Eisai announce NMPA of China approves subcutaneous Leqembi

Eisai (ESAIY) and Biogen (BIIB) announced that the National Medical Products Administration of China has approved the subcutaneous...

29d ago

BIIB

Stoke Therapeutics, Biogen present clinical data of Dravet syndrome candidate

Stoke Therapeutics (STOK) and Biogen (BIIB) announced presentations of data at the 16th European Epilepsy Congress September 5-9...

1M ago

BIIB

STOK

Biogen, Eisai announce positive recommendation for Leqembi in Canada

Eisai (ESAIY) and Biogen Canada (BIIB) announced receipt of the Canada’s Drug Agency’ final positive recommendation supporting public...

1M ago

BIIB

BIIB34 FAQ

What was Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs’s price range in the past 12 months?

Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs lowest stock price was R$110.07 and its highest was R$200.11 in the past 12 months.

What is Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs’s market cap?

Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs’s market cap is R$173.92B.

When is Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs’s upcoming earnings report date?

Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs’s upcoming earnings report date is Oct 28, 2026 which is in 26 days.

How were Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs’s earnings last quarter?

Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs released its earnings results on Jul 29, 2026. The company reported R$0.001 earnings per share for the quarter.

Is Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs overvalued?

According to Wall Street analysts Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs pay dividends?

Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs does not currently pay dividends.

What is Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs’s EPS estimate?

Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs have?

Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs has 886,506,300 shares outstanding.

What happened to Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs’s price movement after its last earnings report?

Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs reported an EPS of R$0.001 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs?

Currently, no hedge funds are holding shares in BR:BIIB34

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology